Pembrolizumab for Early Triple-Negative Breast Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear. METHODS: In this phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin (784 patients; the pembrolizumab-chemotherapy group) or placebo every 3 weeks plus paclitaxel and carboplatin (390 patients; the placebo-chemotherapy group); the two groups then received an additional four cycles of pembrolizumab or placebo, and both groups received doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. After definitive surgery, the patients received adjuvant pembrolizumab or placebo every 3 weeks for up to nine cycles. The primary end points were a pathological complete response at the time of definitive surgery and event-free survival in the intention-to-treat population. RESULTS: At the first interim analysis, among the first 602 patients who underwent randomization, the percentage of patients with a pathological complete response was 64.8% (95% confidence interval [CI], 59.9 to 69.5) in the pembrolizumab-chemotherapy group and 51.2% (95% CI, 44.1 to 58.3) in the placebo-chemotherapy group (estimated treatment difference, 13.6 percentage points; 95% CI, 5.4 to 21.8; P<0.001). After a median follow-up of 15.5 months (range, 2.7 to 25.0), 58 of 784 patients (7.4%) in the pembrolizumab-chemotherapy group and 46 of 390 patients (11.8%) in the placebo-chemotherapy group had disease progression that precluded definitive surgery, had local or distant recurrence or a second primary tumor, or died from any cause (hazard ratio, 0.63; 95% CI, 0.43 to 0.93). Across all treatment phases, the incidence of treatment-related adverse events of grade 3 or higher was 78.0% in the pembrolizumab-chemotherapy group and 73.0% in the placebo-chemotherapy group, including death in 0.4% (3 patients) and 0.3% (1 patient), respectively. CONCLUSIONS: Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy. (Funded by Merck Sharp & Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“improvement in overall survival has been reported in unresectable NSCLC patients and TNBC patients treated with anti PD-L1 antibody with chemotherapy”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Schmid et al., 2020
In the citing paper
“Immune checkpoint blockade (ICB) directed against programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) has shown promising results in TNBC4–6, but the overall response rate of ICB is less than 20%7.”
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Self-citation
Research works printed but not linked: 1
- Qi C Huang M Haiderali A et al. Association between pathological complete responses and long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant chemotherapy. Presented at the NCCN Annual Conference Orlando March 21–23 2019.
Cited by
Items 501–600 of 1,004
Vitale, E., Rizzo, A., Maistrello, L., Cauli, O., Brunetti, O., Monteiro, F. S. M., Soares, A., Santoni, M., Mollica, V., & Massari, F. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s560518 · Cited by 37
Schlam, I. M., Church, S., HETHER, T. D., Chaldekas, K. M., Hudson, B. M., White, A. M., Maisonet, E., Harris, B. T., & Swain, S. M. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03113-9 · Cited by 40
Son, S., Shin, J. M., Shin, S., Kim, C. H., Lee, J. A., Ko, H., Lee, E. S., Jung, J. M., Kim, J., & Park, J. H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121058 · Cited by 34
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer
Howard, F. M., Villamar, D. M., He, G., Pearson, A. T., & Nanda, R. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.1986002 · Cited by 36
Noske, A., Wagner, D., Schwamborn, K., Foersch, S., Steiger, K., Kiechle, M. B., Oettler, D., Karapetyan, S., Hapfelmeier, A., Roth, W., et al. (2021) · The Breast · doi:10.1016/j.breast.2021.11.003 · Cited by 38
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker
Qureshi, S., Chan, N., George, M. A., Ganesan, S., Toppmeyer, D., & Omene, C. O. (2022) · Biomarker Insights · doi:10.1177/11772719221078774 · Cited by 39
Radovich, M., Solzak, J. P., Wang, C. J., Hancock, B. A., Badve, S., Althouse, S. K., Bray, S. M., Storniolo, A. M., Ballinger, T. J., Schneider, B. P., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3078 · Cited by 38
Rapoport, B. L., Nayler, S., Mlecnik, B., Smit, T., Heyman, L., Bouquet, I., Martel, M., Galon, J., Benn, C.-A., & Anderson, R. (2022) · Cancers · doi:10.3390/cancers14102525 · Cited by 33
Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer
Wedam, R., Greer, Y. E., Wisniewski, D. J., Weltz, S., Kundu, M., Voeller, D. M., & Lipkowitz, S. (2023) · Cancers · doi:10.3390/cancers15071936 · Cited by 37
Fusobacterium nucleatum : a novel immune modulator in breast cancer?
Little, A., Tangney, M., Tunney, M. M., & Buckley, N. E. (2023) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2023.9 · Cited by 35
“Furthermore, treatment with ICIs such as atezolizumab has been approved for metastatic TNBC, and pembrolizumab improved clinical outcome for metastatic TNBC and high-risk early-stage TNBC (Refs 141, 142, 143, 144, 145).”
Dixon-Douglas, J. R., & Loi, S. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01087-y · Cited by 41
Xu, W., Li, D., Chen, C., Wang, J., Wei, X., & Yang, X. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202302231 · Cited by 33
Platinum chemotherapy for early triple-negative breast cancer
Mason, S., Willson, M. L., Egger, S. J., Beith, J. M., Dear, R. F.-G., & Goodwin, A. (2024) · The Breast · doi:10.1016/j.breast.2024.103712 · Cited by 35
“This is a shifting target, and the advent of new treatments used in early TNBC such as immunotherapy [33] and poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors [34], as well as the clinical heterogeneity of chemotherapy used in these studies, means the best regimen and timing of…”
BackgroundPont, M., Marqués, M., & Sorolla, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413518 · Cited by 45
“In 2020, the phase III clinical trial KEYNOTE-522 (NCT03036488) revealed the superior efficacy of combining Pembrolizumab with chemotherapy in the neoadjuvant setting compared to chemotherapy alone in terms of complete response rate and event-free survival [25].”
Quintela-Fandiño, M., Holgado, E., Manso, L., Morales, S. M., Bermejo, B., Colomer, R., Apala, J. V., Blanco, R., Muñoz, M., Caleiras, E. J., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01362-y · Cited by 35
B Cells in Breast Cancer Pathology
Li, M., Quintana, Á., Alberts, E., Hung, M. S., Boulat, V., Martí, M., & Grigoriadis, A. E. (2023) · Cancers · doi:10.3390/cancers15051517 · Cited by 36
“has been approved to treat early TNBC patients independently of their PD-L1 status [98,99] and as a first-line treatment combined with chemotherapy for advanced TNBC patients expressing PD-L1 (combined positive score [CPS] of at least 10) [100].”
MethodFattori, S., Roy, A. L., Houacine, J., Robert, L., Abès, R., Gorvel, L., Granjeaud, S., Rouviére, M.-S., Amara, A. B., Boucherit, N., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0613 · Cited by 36
“However, about 40% and 80% of patients with early-stage and advanced TNBC do not respond to chemoimmunotherapy, respectively (3, 4).”
Pembrolizumab in Early Triple-Negative Breast Cancer
Schmid, P., Cortés, J., & Dent, R. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2203316 · Cited by 35
Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution
Tzoras, E., Zerdes, I., Tsiknakis, N., Manikis, G. C., Mezheyeuski, A., Bergh, J. C. S., Matikas, A., & Foukakis, T. (2022) · Cancers · doi:10.3390/cancers14081999 · Cited by 34
“Predictive biomarkers are still lacking as PD-L1 positivity did not predict benefit from ICI in the neoadjuvant setting [10,11] and produced discordant results in metastatic BC patients [7,8].”
BackgroundResultFurukawa, N., Stearns, V., Santa-Maria, C. A., & Popel, A. S. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2170779 · Cited by 37
“The efficacy of immunotherapy in TNBC has been demonstrated in multiple trials including IMpassion130 [34] and KEYNOTE-522 [35] which led to the FDA approval of atezolizumab + chemotherapy (later withdrawn by the manufacturer) for patients with advanced TNBC and pembrolizumab + chemotherapy for patients with high-risk…”
MethodEndorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology
Chaudhuri, A., Kumar, D. N., Dehari, D., Patil, R., Singh, S. K., Kumar, D. K., & Agrawal, A. K. (2023) · Cancers · doi:10.3390/cancers15092661 · Cited by 32
“4 TNBC patients with PDL1 overexpression receiving pembrolizumab plus chemotherapy exhibited prolonged PFS compared to those receiving chemotherapy alone (KEYNOTE-355 trial) [133,150]”
MethodPARP Inhibitors in Breast Cancer: a Short Communication
Daly, G. R., Alrawashdeh, M. M., McGrath, J., Dowling, G. P., Cox, L., Naidoo, S., Varešlija, D., Hill, A. D. K., & Young, L. S. (2024) · Current Oncology Reports · doi:10.1007/s11912-023-01488-0 · Cited by 35
“Moreover, this is not limited to chemotherapeutic agents; immune checkpoint inhibitors (ICIs) have already demonstrated efficacy when combined with chemotherapy in triple-negative breast cancer in the KEYNOTE-522 clinical trial [62].”
BackgroundWang, Y., Chen, Y., Ji, D., Huang, Y., Huang, W., Dong, X., Yao, D., & Wang, D. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02727-7 · Cited by 37
Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology
Mazzeo, R., Sears, J., Palmero, L., Bolzonello, S., Davis, A. A., Gerratana, L., & Puglisi, F. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103700 · Cited by 39
“In locally advanced TNBC, there has been a continual escalation of treatment approaches, as supported by two landmark trials, the KEYNOTE-522 trial 35 and the CREATE-X trial in the adjuvant setting.”
ResultHo, A. Y., Shiao, S. L., Kobald, S. A., Chen, J. H., Duda, D. G., Ly, A., Bossuyt, V., Cho, H. L., Arnold, B. B., Knott, S., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00003 · Cited by 35
“1,48 Our fi ndings of reduced TILs after RT enforced the notion that RT should be administered before or concurrently with ICI, not afterward.”
Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer
Michel, L. L., von Au, A., Mavratzas, A., Smetanay, K., Schütz, F., & Schneeweiß, A. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00730-0 · Cited by 35
Kim, R., & Kin, T. (2021) · Cancers · doi:10.3390/cancers13194756 · Cited by 34
Santisteban, M., Solans, B. P., Hato, L., Urrizola, A., Mejías, L. D., Salgado, E., Sánchez-Bayona, R., Toledo, E., Rodriguez-Spiteri, N., Olartecoechea, B., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211064653 · Cited by 32
Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature
Landry, I., Sumbly, V., & Vest, M. (2022) · Cureus · doi:10.7759/cureus.21970 · Cited by 39
Mehlich, D., & Marusiak, A. A. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215775 · Cited by 37
Neoadjuvant immunotherapy in gastrointestinal cancers – The new standard of care?
Petričević, B., Kabiljo, J., Zirnbauer, R., Walczak, H., Laengle, J., & Bergmann, M. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.015 · Cited by 32
Bagegni, N. A., Davis, A. A., Clifton, K., & Ademuyiwa, F. O. (2022) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s293597 · Cited by 39
“Pembrolizumab in Early-Stage TNBC The phase III KEYNOTE-522 trial was the first randomized, double-blind, placebo-controlled study of pembrolizumab in early-stage TNBC in the neoadjuvant and adjuvant settings.(35) Eligible patients included those with newly diagnosed, high-risk, early-stage TNBC (defined as cT1c, N1-2…”
BackgroundThe DNA damage induced immune response: Implications for cancer therapy
Barros, E. M., McIntosh, S., & Savage, K. I. (2022) · DNA repair · doi:10.1016/j.dnarep.2022.103409 · Cited by 40
“Several studies, including KEYNOTE522 and Impassion031 have shown improved pathological complete response rates achieved by combining ICB with anthracycline-containing chemotherapy regimens [87,88].”
BackgroundLu, T., Zhang, J., Xu-Monette, Z. Y., & Young, K. H. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00432-z · Cited by 40
“ICIs have revolutionized the treatment of solid tumors with PD-L1/2 expression and have become the standard of care for melanoma [101, 102], lung cancer [103, 104], triple-negative breast cancer [105, 106], and urological tumors [107, 108].”
BackgroundBenefits of Breast Cancer Screening and Treatment on Mortality
Wheeler, S. B., Rocque, G. B., & Basch, E. (2024) · JAMA · doi:10.1001/jama.2023.26730 · Cited by 32
Zhao, N., Kabotyanski, E. B., Saltzman, A. B., Malovannaya, A., Yuan, X., Reineke, L. C., Lieu, N., Gao, Y., Pedroza, D. A., Calderon, S. J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci172503 · Cited by 30
“In summary, strategies to augment ICB and chemotherapy are needed for TNBC treatment.”
Influentialde Boo, L. W., Jóźwiak, K., Joensuu, H., Lindman, H., Lauttia, S., Opdam, M., van Steenis, C., Brugman, W., Kluin, R. J. C., Schouten, P. C., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01711-y · Cited by 34
Hwang, K., Elshafeey, N. A., Kotrotsou, A., Chen, H., Son, J. B., Böge, M., Mohamed, R. M. M., Abdelhafez, A. H., Adrada, B. E., Panthi, B., et al. (2023) · Radiology Imaging Cancer · doi:10.1148/rycan.230009 · Cited by 36
Wong, R. S. J., Ong, R. J. M., & Lim, J. S. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.58 · Cited by 31
Ferroptosis Inducers Upregulate PD-L1 in Recurrent Triple-Negative Breast Cancer
Desterke, C., Xiang, Y., Elhage, R., Duruel, C., Chang, Y., & Hamaï, A. (2023) · Cancers · doi:10.3390/cancers16010155 · Cited by 33
“Anti-PD-L1 immunotherapy has been shown to improve pathological complete response of high-risk early triple-negative breast cancer patients who received neo-adjuvant chemotherapy [8].”
BackgroundDiagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review
Zhang, H., Houadj, L., Wu, K. Y., & Tran, S. D. (2024) · Diagnostics · doi:10.3390/diagnostics14030336 · Cited by 38
Mantooth, S. M., Abdou, Y. G., Saez-Ibañez, A. R., Upadhaya, S., & Zaharoff, D. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1385484 · Cited by 32
Kristeleit, R. S., Leary, A. F., Oaknin, A., Redondo, A., George, A. J., Chui, S., Seiller, A., Liste-Hermoso, M., Willis, J., Shemesh, C. S., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02776-7 · Cited by 35
Gut microbiota interact with breast cancer therapeutics to modulate efficacy
Arnone, A. A., Ansley, K. C., Heeke, A. L., Howard-McNatt, M. M., & Cook, K. L. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00185-0 · Cited by 44
“For example, pembrolizumab (an anti-programmed cell death protein 1 (PD-1) antibody) has been approved in combination with chemotherapy to treat both early-stage and metastatic triple-negative breast cancer (Cortes et al, 2022; Schmid et al, 2020).”
Advancing immunotherapy for early-stage triple-negative breast cancer
Cosimo, S. D. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31962-0 · Cited by 33
Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer
Noguchi, E., Shien, T., & Iwata, H. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa230 · Cited by 30
A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer
Nederlof, I., Horlings, H. M., Curtis, C. N., & Kok, M. (2021) · Cancers · doi:10.3390/cancers13020316 · Cited by 34
Role of Platinums in Triple-Negative Breast Cancer
Lynce, F. C., & Nunes, R. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01041-x · Cited by 33
Managing side effects of immune checkpoint inhibitors in breast cancer
Criscitiello, C., Corti, C., Pravettoni, G., & Curigliano, G. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103354 · Cited by 34
Treatment Strategies for Oligometastatic Breast Cancer
Nesbit, E. G., Donnelly, E. D., & Strauss, J. B. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00889-2 · Cited by 31
Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis
Saleh, R., Nadler, M. B., Desnoyers, A., Meti, N., Fazelzad, R., & Amir, E. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102283 · Cited by 31
Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies
Sakach, E. A., O'Regan, R. M., Meisel, J. L., & Li, X. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.09.003 · Cited by 34
Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies
Belli, C., Antonarelli, G., Repetto, M., Bielo, L. B., Crimini, E., & Curigliano, G. (2022) · Cancers · doi:10.3390/cancers14174278 · Cited by 33
Tailored axillary surgery – A novel concept for clinically node positive breast cancer
Heidinger, M., Knauer, M., Tausch, C., & Weber, W. P. (2023) · The Breast · doi:10.1016/j.breast.2023.03.005 · Cited by 30
Peng, W., Jin, X., Xu, X., Yang, Y., Ma, D., Shao, Z., & Jiang, Y. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2143 · Cited by 34
Wilkinson, A. N., Seely, J. M., Rushton, M. K., Williams, P., Cordeiro, E., Allard-Coutu, A., Hong, N. J. L., Moideen, N., Robinson, J., Renaud, J., et al. (2023) · Current Oncology · doi:10.3390/curroncol30090571 · Cited by 34
“Patients with TNBC T1b or greater were assumed to be treated with chemotherapy, while patients with stages II and III also received pembrolizumab [50].”
BackgroundRíos-Hoyo, A., Cobain, E. F., Huppert, L. A., Beitsch, P. D., Buchholz, T. A., Esserman, L. J., Veer, L. V. ‘., Rugo, H. S., & Pusztai, L. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02614 · Cited by 31
Morrison, L., & Okines, A. F. C. (2023) · Cancers · doi:10.3390/cancers15153801 · Cited by 33
“will have additionally been exposed to immunotherapy with the anti-PD1 monoclonal antibody, pembrolizumab [6].”
BackgroundFarooq, M. U., Lawrie, C. H., & Deng, N. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.150356 · Cited by 33
Present and Future of Immunotherapy for Triple-Negative Breast Cancer
Sriramulu, S., Thoidingjam, S., Speers, C. W., & Nyati, S. (2024) · Cancers · doi:10.3390/cancers16193250 · Cited by 34
“Pembrolizumab and chemotherapy combination has consistently increased pCR in multiple clinical trials (I-SPY2 [137], KEYNOTE-173 [66], and KEYNOTE-522 [66]) in patients with early-stage TNBC.”
BackgroundMethodInfluentialEpidermal growth factor receptor mutations in breast Cancer: Therapeutic challenges and way forward
Shetty, S. R., Kar, T., & Das, A. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.108037 · Cited by 32
The distinct roles of ROS in tumor immunity: from mechanisms to immunotherapeutic applications
Li, J., Huang, C., Tang, P., Wu, R., Wu, Q., & Zhang, C. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01780-z · Cited by 42
“…these debates converge on a central translational question: is ROS itself a druggable target, as evidenced by the success of ROS-inducing chemo-immunotherapies [222–225] and nanomedicines [278, 291, 335], or is its true utility as a predictive biomarker for patient stratification [235, 236]?”
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
Ahn, S. G., Kim, S., Shepherd, J. H., Cha, Y. J., Bae, S. J., Kim, C., Jeong, J., & Perou, C. M. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06193-9 · Cited by 28
Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer
Hyder, T., Bhattacharya, S., Gade, K., Nasrazadani, A., & Brufsky, A. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s273058 · Cited by 33
Research advances and new challenges in overcoming triple-negative breast cancer
Zong, Y., & Pegram, M. D. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.04 · Cited by 46
Clinical Progress of PD-1/L1 Inhibitors in Breast Cancer Immunotherapy
Chen, F., Chen, N., Gao, Y., Jia, L., Lyu, Z., & Cui, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.724424 · Cited by 36
Anthracyclines in the treatment of patients with early breast cancer
Guarneri, V., & de Azambuja, E. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100461 · Cited by 31
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside
Meattini, I., Livi, L., Lorito, N., Becherini, C., Bacci, M., Visani, L., Fozza, A., Belgioia, L., Loi, M., Mangoni, M., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102417 · Cited by 31
Montagna, G., Lee, M. K., Sevilimedu, V., Barrio, A. V., & Morrow, M. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12240-6 · Cited by 31
Garufi, G., Carbognin, L., Schettini, F., Seguí, E., Leone, A. D., Franco, A., Paris, I., Scambia, G., Tortora, G., & Fabi, A. (2022) · Cancers · doi:10.3390/cancers14174064 · Cited by 29
“The assessment of the association between pCR and TILs count is expected [61].”
BackgroundInfluentialAntibody–Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond—A 2023 Review
Xiao, T., Ali, S., Mata, D. G. D. M. M., Lohmann, A. E., & Blanchette, P. (2023) · Current Oncology · doi:10.3390/curroncol30070474 · Cited by 31
Impact of HIV infection on baseline characteristics and survival of women with breast cancer
Brandão, M., Bruzzone, M., Franzoi, M. A., Angelis, C. D., Eiger, D., Caparica, R., Piccart, M. J., Buisseret, L., Ceppi, M., Dauby, N., et al. (2020) · AIDS · doi:10.1097/qad.0000000000002810 · Cited by 29
Sofianidi, A. A., Dumbrava, E. E. I., Syrigos, K. N., & Nasrazadani, A. (2024) · Cancers · doi:10.3390/cancers16061139 · Cited by 35
“They could be helpful in overcoming the issues posed by current treatments, such as the risk of autoimmune-related adverse events associated with immunotherapy [23].”
BackgroundAxillary Surgery for Breast Cancer in 2024
Heidinger, M., & Weber, W. P. (2024) · Cancers · doi:10.3390/cancers16091623 · Cited by 28
“Indications for NACT were extended from initially locally advanced BC to cases with node-negative disease [87,88].”
BackgroundCost-Effectiveness of Breast Cancer Screening Using Digital Mammography in Canada
Wilkinson, A. N., Mainprize, J. G., Yaffe, M. J., Robinson, J., Cordeiro, E., Hong, N. J. L., Williams, P., Moideen, N., Renaud, J., Seely, J. M., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.52821 · Cited by 39
Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond
Agelidis, A. M., Ter‐Zakarian, A., & Jaloudi, M. (2025) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s516125 · Cited by 67
“35 This also yielded the benefit of avoiding morbid complete axillary lymph node dissections in more patients.”
Li, Y.-R., Shen, X., Zhu, Y., Li, Z., Hon, R., Tian, Y., Huang, J. S., Zhao, A., Nathan, Y., Zhang, C., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01736-9 · Cited by 39
Kyte, J. A., Røssevold, A., Falk, R. S., & Naume, B. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02424-7 · Cited by 28
Wolfson, B., Padget, M. R., Schlom, J., & Hodge, J. W. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002258 · Cited by 29
Immunomodulating Therapies in Breast Cancer—From Prognosis to Clinical Practice
Schmidt, M., & Heimes, A.-S. (2021) · Cancers · doi:10.3390/cancers13194883 · Cited by 30
Howard, J., Goh, C. Y., Weiner‐Gorzel, K., Higgins, M. J., & McCann, A. H. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101247 · Cited by 32
Villacampa, G. J., Tolosa, P., Salvador, F., Sánchez-Bayona, R., Villanueva, L., Dienstmann, R., Ciruelos, E., & Pascual, T. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102352 · Cited by 35
Han, M. G., Wee, C. W., Kang, M. H., Kim, M. J., Jeon, S. H., & Kim, I. A. (2022) · Cancers · doi:10.3390/cancers14112692 · Cited by 30
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Bylsma, S. A., Yun, K. M., Patel, S. P., & Dennis, M. J. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00995-9 · Cited by 32
Local Breast Microbiota: A “New” Player on the Block
Vitorino, M. M., Costa, D. A., Vicente, R. S., Caleça, T., & Santos, C. (2022) · Cancers · doi:10.3390/cancers14153811 · Cited by 30
“In the metastatic setting, the IMpassion 130 trial reported that CD8 cell infiltration was predictive of overall survival benefit with atezolizumab while the Ventana SP142 PD-L1 assay also predicted the benefit for that drug [87].”
BackgroundBonadio, R. C., Tarantino, P., Testa, L., Punie, K., Pernas, S., Barrios, C. H., Curigliano, G., Tolaney, S. M., & Barroso‐Sousa, R. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102459 · Cited by 29
Bobrie, A., Massol, O., Ramos, J., Mollévi, C., Lopez‐Crapez, E., Bonnefoy, N., Boissière‐Michot, F., & Jacot, W. (2022) · Cancers · doi:10.3390/cancers14194829 · Cited by 29
“Very recently, the combination of immunotherapy with chemotherapy has been approved for neoadjuvant and first-line treatment of metastatic TNBC [16,17].”
BackgroundAsleh, K., Lluch, A. M., Goytain, A., Barrios, C. H., Wang, X. Q., Torrecillas, L., Gao, D., Ruíz-Borrego, M., Leung, S. C. Y., Bines, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2191 · Cited by 30
“In contrast, patients with basal-like immune – activated pro fi le might be better candidatesfortheimmunotherapyofpembrolizumab,basedonrecent results from KEYNOTE-522 (10).”
InfluentialSun, M., Shi, W., Wu, Y., He, Z., Sun, J., Cai, S., & Luo, Q. (2022) · Advanced Science · doi:10.1002/advs.202205247 · Cited by 28
Lang, J. E., Forero, A., Yee, D., Yau, C. S. F., Wolf, D. M., Park, J., Parker, B. A., Chien, A. J., Wallace, A. M., Murthy, R. K., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00493-z · Cited by 31
Neoadjuvant Immunotherapy: A Promising New Standard of Care
Boydell, E., Sandoval, J. L., Michielin, O. A., Obéid, M., Addeo, A., & Friedlaender, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411849 · Cited by 33
“These data have supported the development of many clinical trials, including the phase III KEYNOTE-522 and CHECKMATE-816 trials, which led to the FDA approval of neoadjuvant pembrolizumab in early triple-negative breast cancer and neoadjuvant nivolumab in resectable non-small cell lung cancer (NSCLC).”
BackgroundInfluentialXue, L., Wang, C., Qian, Y., Zhu, W., Liu, L., Yang, X., Zhang, S., & Luo, D. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111196 · Cited by 31
Wu, H.-Y., Lin, C.-Y., Tzeng, Y. T., Hung, C., Liu, S., Yin, C.-H., Chen, J., Chen, Y.-S., & Yang, J.-R. (2023) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001034 · Cited by 31
Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer
Yndestad, S., Engebrethsen, C., Herencia-Ropero, A., Nikolaienko, O., Vintermyr, O. K., Lillestøl, R., Minsaas, L., Leirvaag, B., Iversen, G. T., Gilje, B., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00338 · Cited by 32
Immunotherapy and Radiation Therapy Sequencing in Breast Cancer: A Systematic Review
Verma, S., Young, S., Boldt, G., Blanchette, P., Lock, M. I., Helou, J. A., & Raphael, J. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.01.001 · Cited by 29
Liu, C., Qian, X., Yu, C., Xia, X., Li, J., Li, Y., Xie, Y., Gao, G., Song, Y., Zhang, M., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216642 · Cited by 29
Breast cancer and cardiovascular health
López‐Fernández, T., Clement, I. M., Aznar, M. C., Barac, A., Bergler-Klein, J. K., Meattini, I., Scott, J. M., Cardinale, D. M., & Dent, S. F. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae637 · Cited by 35
Boissière‐Michot, F., Chateau, M., Thézenas, S., Lafont, V., Lopez‐Crapez, E., Sharma, P., Bobrie, A., Roger, P., Guiu, S., & Jacot, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1507371 · Cited by 28
McArthur, H. L., Tolaney, S. M., Dent, R. A., Schmid, P., Asselah, J., Liu, Q., Meisel, J. L., Niikura, N., Park, Y. H., Werutsky, G., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251316176 · Cited by 44
Clinico-pathological factors predicting pathological response in early triple-negative breast cancer
Helal, C., Djerroudi, L., Ramtohul, T., Laas, E., Vincent‐Salomon, A., Jin, M., Seban, R., Bièche, I., Bello-Roufai, D., Bidard, F., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00729-8 · Cited by 30
“14 , in which only patients with ER expression 1% were included.”
Influential
Metadata
- Authors
- Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., Takahashi, M., Foukakis, T., Fasching, P. A., Cardoso, F., Untch, M., Jia, L., Karantza, V., Zhao, J., Aktan, G., Dent, R., & O’Shaughnessy, J.
- Affiliations
- Queen Mary University of London (GB)
- IOB Institute of Oncology, Quiron Group;Vall d’Hebron Institute of Oncology (VHIO), Madrid & Barcelona, Spain
- Yale Cancer Center (US)
- Cedars-Sinai Medical Center (US)
- Kliniken Essen-Mitte (DE)
- Karolinska University Hospital (SE)
- Philipps University of Marburg (DE)
- Samsung Medical Center (KR)
- The University of Sydney (AU)
- Ludwig-Maximilians-Universität München (DE)
- Sapporo National Hospital (JP)
- Universitätsklinikum Erlangen (DE)
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
- Helios Hospital Berlin-Buch (DE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- National University of Singapore (SG)
- Baylor University Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-27
- Volume
- 382
- Issue
- 9
- Pages
- 810-821
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3006930853
- Cited by
- 3,270
- References
- 31
- Citations by year
- 2026: 580 · 2025: 576 · 2024: 552 · 2023: 500 · 2022: 514 · 2021: 391 · 2020: 152
- FWCI
- 133.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (N/A)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
- Keywords
- pembrolizumab, triple-negative breast cancer, early breast cancer, neoadjuvant immunotherapy, neoadjuvant chemotherapy, paclitaxel, carboplatin, pathological complete response, event-free survival, immune checkpoint inhibitors, doxorubicin-cyclophosphamide, epirubicin-cyclophosphamide
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Female, Humans, Middle Aged, Neoplasm Staging, Epirubicin, Carboplatin, Paclitaxel, Neoadjuvant Therapy, Kaplan-Meier Estimate, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.